Geron (NASDAQ:GERN – Get Rating) will be posting its quarterly earnings results after the market closes on Monday, May 9th. Analysts expect Geron to post earnings of ($0.11) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Geron (NASDAQ:GERN – Get Rating) last posted its earnings results on Thursday, March 10th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.02). The firm had revenue of $1.04 million for the quarter, compared to analysts’ expectations of $0.10 million. Geron had a negative return on equity of 70.87% and a negative net margin of 8,335.39%. During the same quarter in the previous year, the firm posted ($0.07) earnings per share. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
GERN traded down $0.06 during trading on Tuesday, reaching $1.44. 18,776 shares of the stock were exchanged, compared to its average volume of 2,152,012. The business’s 50 day moving average price is $1.31 and its two-hundred day moving average price is $1.31. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.11 and a quick ratio of 4.11. The company has a market capitalization of $464.55 million, a price-to-earnings ratio of -4.08 and a beta of 0.99. Geron has a 1 year low of $0.99 and a 1 year high of $2.23.
Institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC acquired a new position in Geron in the third quarter valued at $33,000. Royal Bank of Canada increased its stake in Geron by 36.9% in the third quarter. Royal Bank of Canada now owns 29,073 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 7,830 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Geron by 99.7% in the third quarter. BNP Paribas Arbitrage SA now owns 68,506 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 34,204 shares during the last quarter. Metropolitan Life Insurance Co NY increased its stake in Geron by 22.3% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 85,307 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 15,554 shares during the last quarter. Finally, Invesco Ltd. increased its stake in Geron by 31.7% in the second quarter. Invesco Ltd. now owns 113,566 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 27,337 shares during the last quarter. Hedge funds and other institutional investors own 47.75% of the company’s stock.
About Geron (Get Rating)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
- Get a free copy of the StockNews.com research report on Geron (GERN)
- Another Buy The Dip Opportunity In Freshpet
- Inflation Wreaks Havoc On Haverty Furniture Company
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- It’s Time to Book an Appointment for Teladoc Stock
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.